Gérard Krause

Gérard Krause

Auto-generated profile, based on publicly available information

Gérard Krause

Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in The Lancet
Verified
Journal Article
Closed access
ASAparna Schweitzer
Aparna Schweitzer
JHJohannes Horn
Johannes Horn
RMRafael T Mikolajczyk
Rafael T Mikolajczyk
GKGérard Krause
Gérard Krause
JOJördis J Ott
Jördis J Ott

10 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CFChristina Frank
Christina Frank
DWDirk Werber
Dirk Werber
JCJakob P. Cramer
Jakob P. Cramer
MAMona Askar
Mona Askar
MFMirko Faber
Mirko Faber
GKGérard Krause
Gérard Krause
We describe an outbreak of gastroenteritis and the hemolytic–uremic syndrome caused by Shiga-toxin–producing Escherichia coli in Germany in May, June, and July, 2011. The consumption of sprouts was identified as the most likely vehicle of infection.

5 July 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
AYAdesola Yinka-Ogunleye
Adesola Yinka-Ogunleye
OAOlusola Aruna
Olusola Aruna
MDMahmood Dalhat
Mahmood Dalhat
DODimie Ogoina
Dimie Ogoina
AMAndrea McCollum
Andrea McCollum
PSPanayampalli S. Satheshkumar
Panayampalli S. Satheshkumar

10 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
UBUdo Buchholz
Udo Buchholz
HBHelen Bernard
Helen Bernard
DWDirk Werber
Dirk Werber
MBMerle M. Böhmer
Merle M. Böhmer
CRCornelius Remschmidt
Cornelius Remschmidt
MKMichael Kühne
Michael Kühne
A large outbreak of the hemolytic–uremic syndrome caused by Shiga-toxin–producing Escherichia coli O104:H4 occurred in Germany in May 2011. The source of infection was undetermined.

5 July 2011 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MKMaria Van Kerkhove
Maria Van Kerkhove
KVKatelijn A. H. Vandemaele
Katelijn A. H. Vandemaele
VSVivek Shinde
Vivek Shinde
GJGiovanna Jaramillo-Gutierrez
Giovanna Jaramillo-Gutierrez
AKArtemis Koukounari
Artemis Koukounari
AMAnthony W. Mounts
Anthony W. Mounts
Since the start of the 2009 influenza A pandemic (H1N1pdm), the World Health Organization and its member states have gathered information to characterize the clinical severity of H1N1pdm infection and to assist policy makers to determine risk groups for targeted control measures. Data were collected on approximately 70,000 laboratory-confirmed hospitalized H1N1pdm patients, 9,700 patients admitted to intensive care units (ICUs), and 2,500 deaths reported between 1 April 2009 and 1 January 2010 from 19 countries or administrative regions—Argentina, Australia, Canada, Chile, China, France, Germany, Hong Kong SAR, Japan, Madagascar, Mexico, the Netherlands, New Zealand, Singapore, South Africa, Spain, Thailand, the United States, and the United Kingdom—to characterize and compare the distribution of risk factors among H1N1pdm patients at three levels of severity: hospitalizations, ICU admissions, and deaths. The median age of patients increased with severity of disease. The highest per capita risk of hospitalization was among patients <5 y and 5–14 y (relative risk [RR] = 3.3 and 3.2, respectively, compared to the general population), whereas the highest risk of death per capita was in the age groups 50–64 y and ≥65 y (RR = 1.5 and 1.6, respectively, compared to the general population). Similarly, the ratio of H1N1pdm deaths to hospitalizations increased with age and was the highest in the ≥65-y-old age group, indicating that while infection rates have been observed to be very low in the oldest age group, risk of death in those over the age of 64 y who became infected was higher than in younger groups. The proportion of H1N1pdm patients with one or more reported chronic conditions increased with severity (median = 31.1%, 52.3%, and 61.8% of hospitalized, ICU-admitted, and fatal H1N1pdm cases, respectively). With the exception of the risk factors asthma, pregnancy, and obesity, the proportion of patients with each risk factor increased with severity level. For all levels of severity, pregnant women in their third trimester consistently accounted for the majority of the total of pregnant women. Our findings suggest that morbid obesity might be a risk factor for ICU admission and fatal outcome (RR = 36.3). Our results demonstrate that risk factors for severe H1N1pdm infection are similar to those for seasonal influenza, with some notable differences, such as younger age groups and obesity, and reinforce the need to identify and protect groups at highest risk of severe outcomes. Please see later in the article for the Editors' Summary

30 September 2020 in Nature Immunology
Verified
Journal Article
Open access
PDF file
ANAnnika Nelde
Annika Nelde
TBTatjana Bilich
Tatjana Bilich
JHJonas S. Heitmann
Jonas S. Heitmann
YMYacine Maringer
Yacine Maringer
HSHelmut R. Salih
Helmut R. Salih
JWJuliane S. Walz
Juliane S. Walz
T cell immunity is central for the control of viral infections. To characterize T cell immunity, but also for the development of vaccines, identification of exact viral T cell epitopes is fundamental. Here we identify and characterize multiple dominant and subdominant SARS-CoV-2 HLA class I and HLA-DR peptides as potential T cell epitopes in COVID-19 convalescent and unexposed individuals. SARS-CoV-2-specific peptides enabled detection of post-infectious T cell immunity, even in seronegative convalescent individuals. Cross-reactive SARS-CoV-2 peptides revealed pre-existing T cell responses in 81% of unexposed individuals and validated similarity with common cold coronaviruses, providing a functional basis for heterologous immunity in SARS-CoV-2 infection. Diversity of SARS-CoV-2 T cell responses was associated with mild symptoms of COVID-19, providing evidence that immunity requires recognition of multiple epitopes. Together, the proposed SARS-CoV-2 T cell epitopes enable identification of heterologous and post-infectious T cell immunity and facilitate development of diagnostic, preventive and therapeutic measures for COVID-19.